New York, December 3, 2025 – U.S. stocks delivered another dose of heart-stopping volatility yesterday, with biotech and small-cap names stealing the spotlight in a session that saw extreme bifurcated action. As the S&P 500 and Nasdaq eked out modest gains amid Fed rate-cut speculation, a handful of overlooked plays exploded while others imploded, underscoring the market's razor-thin divide between winners and wipeouts.
Data as of 4:15 PM ET on December 2 revealed a classic "risk-on" tale for speculative sectors, but with brutal consequences for the laggards.
Yesterday's Top 5 Most Advanced Stocks
- PLRZ (Polyrzon Ltd.) ↑ 131.96% – Tiny biotech firm on breakthrough trial data hype
- PERF (Perfect Corp.) ↑ 103.92% – AI beauty tech play surges on partnership rumors
- HSPOW (Horizon Space Acquisition) ↑ 85.64% – SPAC deal frenzy in aerospace
- EB (Eventbrite, Inc.) ↑ 78.63% – Event platform rebounds on holiday booking boom
- CELG ↑ 77.02% – Celgene successor rides pipeline momentum
Yesterday's Top 5 Most Declined Stocks
- SEVVNR (Seven Hills Realty Trust) ↓ 65.61% – REIT crushed on debt restructuring fears
- SONN (Sonnet BioTherapeutics) ↓ 59.35% – Clinical trial setback tanks the stock
- JANX (Janux Therapeutics) ↓ 53.39% – Immunotherapy developer hit by FDA delay buzz
- ABTC (American Bitcoin Corp.) ↓ 38.83% – Crypto miner slammed amid Bitcoin dip
- NRSNW (NeuroSense Therapeutics) ↓ 38.81% – ALS drug candidate fails key milestone
The biotech blowout led the charge, with PLRZ and PERF posting gains that turned $10,000 positions into $23,000+ overnight – fueled by retail frenzy on platforms like Robinhood. Eventbrite's pop came on surging ticket sales data, while SPACs like HSPOW benefited from merger speculation.
On the flip side, the carnage in REITs and biotechs was merciless: Seven Hills Realty's 65% free-fall erased $200 million in market cap, triggered by lender concerns, while Sonnet and Janux suffered from pipeline setbacks that spooked investors.
Market watchers attribute the extremes to thin holiday liquidity and positioning ahead of today's jobs report, which could sway Fed cut odds (now at 85% for December). With the VIX spiking 5% to 15.2, traders are bracing for more whipsaws.
Yesterday was a reminder that in this market, fortunes flip faster than ever – biotech bulls feasted, but the bears left a trail of destruction. Stay strapped in; the ride's just heating up.
